Neurocrine Biosciences, Inc. Stock News

Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2026. "Our third quarter performance marks another important milestone in Neuro...

BootCAHmp® delivers evidence-based education to strengthen understanding of classic congenital adrenal hyperplasia through interactive learning and real-world patient cases DiscoverCAH™ provides immersive virtual experiences to expand knowledge of classic congenital adrenal hyperplasia through realistic patient scenarios SAN DIEGO, Oct. 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nas...

New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with INGREZZA®(valbenazine) capsules The 6-point threshold helps contextualize the meaningful improvement with INGREZZA observed in the KINECT-PRO™ study, including a mean 13.1-point improvement in EQ Vi...

Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for patients and families beyond obesity-related complications The manuscript underscores the importance of multidimensional assessment and integrated care management across the patient lifespan Experts con...

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease. NBI-'567 is an orally administered, M1/M4 (M1 preferring) selective muscarinic agonist being evaluated as an adjunctive treatment for cognitive imp...

Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records showed growth and bone-age monitoring in childhood; puberty and reproductive health concerns through adolescence and young adulthood; and increasingly diverse clinical needs in adulthood, while treatmen...

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W.